OBB Newsletter

  • Enter your e-mail address below to subscribe to the Orange Book Blog newsletter. If a new post is added during the day, you'll receive it by e-mail the next morning.

Enter your email address:

Delivered by FeedBurner

AddThis Feed Button

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is Aaron Barkoff's personal website and it is intended primarily for other attorneys. Orange Book Blog is not edited by McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB") or its clients. Therefore, no part of Orange Book Blog--whether information, commentary, or other--may be attributed to MBHB or its clients. Readers should be aware that MBHB represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MBHB clients. Orange Book Blog will always strive to be unbiased in its reporting. All information on Orange Book Blog should be double-checked for its accuracy and current applicability. -- © Aaron F. Barkoff 2006-08

« Barr and Caraco Win Summary Judgment that Ortho-McNeil's Formulation Patent on Ultracet is Invalid | Main | OBB News Briefs »

May 02, 2008

ACI "In-House Counsel Forum on Pharmaceutical Antitrust," National Harbor, Maryland, May 20-21

American Conference Institute is holding its fourth annual "Pharmaceutical Antitrust" conference on May 20-21, in National Harbor, Maryland.

According to ACI, at the conference, "leading in-house pharmaceutical counsel, government regulators, and expert attorneys will provide practical advice on how to successfully tackle the most complex antitrust issues facing brand-name and generic pharmaceutical companies."

Several of the presentations look particularly interesting:

  • A Keynote Address by Stephen Calkins, Former General Counsel of the Federal Trade Commission
  • "Assessing What the Authorized Generic Study and Report on Intellectual Property Collectively Mean for the Pharmaceutical Industry"
  • "The Law of Hatch-Waxman Patent Infringement Settlements and Where it is Going"
  • "Congressional Action on Pharmaceutical Patent Settlements: Pending Legislation and Strategies to Employ"
  • "Life Cycle Management Strategies for Protecting Your Product and Reducing Antitrust Exposure"
  • "DOJ Perspective on Recent Developments in Antitrust and IP Law"
  • A Keynote Address by Jon Leibowitz, Commissioner, Federal Trade Commission

The conference also features a Master Class on May 2: "Navigating the Pharmaceutical Merger Process."

For more information or to register, please visit the conference website.

Comments

Post a comment

Comments are moderated, and will not appear on this weblog until the author has approved them.